Diabetic retinopathy (DR) affects over 93 million people worldwide and is the number one cause of blindness among working age adults. These indicators coupled with the projected rise of patients diagnosed with diabetes, makes DR a serious and prevalent vision threating disease. Data from recent clinical trials demonstrate that in addition to the well accepted role of hyperglycemia, dyslipidemia is an important, but often overlooked factor in the development of DR. The central aim of this review article is to showcase the critical role of dyslipidemia in DR progression as well as highlight novel therapeutic solutions that take advantage of the vital roles lipid metabolism plays in DR progression.
Diabetic dyslipidemia and DR progression
The role of lipids in the progression of DR can be documented back to the 1950s when Keiding et al. demonstrated a correlation between the formation of hard exudates and serum lipid levels (Keiding, Mann, Root, Lawry, & Marble, 1952) . It was further confirmed by studies examining dietary lipid interventions (Houtsmuller, Zahn, & Henkes, 1980; Howard-Williams et al., 1985; King & Dobree, 1963) . More recently, analysis of blood lipid profiles in Diabetes Control and Complications Trial (DCCT) samples established a tight association between the development of DR and dyslipidemia in type 1 diabetes, and several clinical trials using lipid lowering medications suggested a link between dyslipidemia and DR progression in type 2 diabetes (Action to Control Cardiovascular Risk in Diabetes Follow-On, 2016; Frank, 2014; Matthews, 2011; Wright & Dodson, 2011) . Specifically, administration of peroxisome proliferator-activated receptor alpha (PPARa) activator, clofibrate (prototype of fenofibrate) found reductions in hard exudates (Cullen, Town, & Campbell, 1974; Duncan et al., 1968; Harrold, Marmion, & Gough, 1969) , and the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study demonstrated that fenofibrate treatment resulted in a significant reduction in the need for laser therapy for DR at 5 years (Keech et al., 2007) . The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study showed that patients with type 2 diabetes who received both fenofibrate and HMG-CoA reductase inhibitor simvastatin, to control triglyceride and cholesterol levels respectively, had less progression of DR at 4 years (Action to Control Cardiovascular Risk in Diabetes Follow-On, 2016).
Dyslipidemia is a complex disorder that involves both central, as well as organ-specific mechanisms Chen, Esselman, Jump, & Busik, 2005; Tikhonenko et al., 2010; Yu & Lyons, 2005) . These include abnormal levels of lipids in the plasma that arise from a disproportion in metabolism, release and/or uptake by the adipose tissue as well as inefficient lipid removal from blood circulation. In addition to central regulation, most cells in the body have tissue-specific control of lipid uptake, remodeling and elimination Mast et al., 2011; Schultz et al., 2000; Tikhonenko et al., 2010; Wang et al., 2005; Zechner, 1997) . Diabetes affects both central and retinal tissue-specific control of multiple lipid classes including fatty acids, triglycerides, cholesterol, and sphingolipids (Busik, Esselman, & Reid, 2012; Hazra et al., 2012; Tikhonenko et al., 2010) . Moreover, insulin resistance has been shown to promote dyslipidemia by elevating LDL cholesterol, total cholesterol, free fatty acids and triglycerides as well as decreasing HDL cholesterol and inhibiting reverse cholesterol transport genes http://dx.doi.org/10.1016/j.visres.2017.04.010 0042-6989/Ó 2017 Elsevier Ltd. All rights reserved. (Ginsberg, Zhang, & Hernandez-Ono, 2005; Goff, D'Agostino, Haffner, & Otvos, 2005; Reaven & Chen, 1988) . Patients with diabetic dyslipidemia were shown to have higher frequency of acquiring retinal irregularities (Cetin et al., 2013; Sacks et al., 2014) . However, unlike macrovascular complications, where direct correlation between pathology and circulating lipid levels is well established (The ACCORD Study Group and ACCORD Eye Study Group, 2010) , the role of circulating lipids in microvascular complications is still controversial. Indeed, Wisconsin Epidemiologic Study of Diabetic Retinopathy found no association between total cholesterol or high density lipoprotein (HDL) and incidence of DR or macular edema, while there was a modest association between higher levels of HDL and decreased prevalence of proliferative DR (Klein, Myers, Howard, & Klein, 2015) . In the ACCORD follow-up study, ACCORD Follow-On Eye Study (ACCORDION), the beneficial effects of dual fenofibrate and simvastatin treatment disappeared 8 years after randomization in the original ACCORD study, although the effects of glycemic control persisted.
Thus, although there is an association between lipid control and the progression of retinopathy, the nature of this association is not well understood. In this review, we will discuss the effect of diabetes on systemic and retina-specific lipid changes as it relates to the pathogenesis of diabetic retinopathy.
Fatty acyls
Both systemic and retinal-specific fatty acid profiles are affected by diabetes and were suggested to contribute to the progression of DR. At the systemic level, diabetic patients have significantly elevated levels of triglyceride in skeletal muscle and blood when compared to non-diabetic patients (Sinha et al., 2002) with the severity of diabetes positively correlating with serum triglycerides (Cetin et al., 2013; Sacks et al., 2014) . Specifically, in the liver under non-disease conditions, insulin promotes the conversion of fatty acids to triglycerides, followed by their secretion as very-low density lipoproteins (VLDL) Busik et al., 2012; Weinstock et al., 1997 . However, during diabetic conditions where insulin levels are low or in cases of insulin resistance, plasma lipids levels as well as the composition of fatty acids, are dramatically altered (Goldberg, 1981 (Goldberg, , 2001 Goldberg & Capuzzi, 2001; Poisson, 1989; Vessby, 2000) . Altered plasma fatty acid composition can contribute to both retinal, and bone-marrow-derived inflammatory as well as progenitor cell membrane composition and function (Lydic, Renis, Busik, & Reid, 2009; Opreanu et al., 2011; Tikhonenko et al., 2010 Tikhonenko et al., , 2013 .
In addition to the uptake from circulation, retina has very active lipid metabolism leading to remodeling of fatty acids (Tikhonenko et al., 2010) . Therefore, retina has a fatty acid profile that is very distinct from that of blood plasma or liver, and retinal fatty acids are significantly altered by diabetes Opreanu et al., 2011; Tikhonenko et al., 2010) . Retinal saturated and unsaturated fatty acids are remodeled through a series of elongation and desaturation reactions (Tikhonenko et al., 2010) . It has been demonstrated that diabetes can cause a significant reduction in levels of elongase enzymes (Tikhonenko et al., 2010; Wang et al., 2006) . A decrease in retinal levels of one of the highest retinal n-3 polyunsaturated fatty acids (PUFA)-docosahexaenoic acid (DHA) is observed due to, at least in part, diabetes-induced alterations in fatty acid remodeling in the retina (Connor et al., 2007; Futterman & Kupfer, 1968; Tikhonenko et al., 2010) .
Sterol lipids
In the retina, cholesterol levels are determined by several factors. These include systemic delivery, local production, as well as elimination of cholesterol (Fliesler, 2015; Fliesler & Bretillon, 2010; Fliesler, Florman, Rapp, Pittler, & Keller, 1993) . Unlike the brain, which solely relies on local synthesis of cholesterol, the retina employs the Low-Density Lipoprotein Receptor (LDLR)-mediated pathway to deliver cholesterol obtained from diet or produced by the liver (Fliesler & Keller, 1995; Fliesler et al., 1993) . Specifically, this blood-borne cholesterol is delivered to the retina predominantly via the retinal pigmented epithelium (RPE) layer Pikuleva & Curcio, 2014; Elner, 2002 . Previous studies demonstrated that increased levels of LDL cholesterol pass through this retinal-blood barrier in the diabetic retina when compared to non-diabetic conditions (Du et al., 2013 ) Fliesler et al., 1993 . In addition to increased LDL uptake through REP layer, increased permeability of retinal capillaries was shown to cause extravasation of plasma lipoproteins (Du et al., 2013; Wu & Lyons, 2011; Wu et al., 2008) . Local synthesis of cholesterol has been shown to be primarily carried out by the Müller cells as well as photoreceptor inner segments (Mast et al., 2011; Pikuleva & Curcio, 2014; Zheng et al., 2012) . Moreover, unlike other organs, the retina relies on active processes to remove cholesterol Pikuleva, 2008; Zheng, Mast, Saadane, & Pikuleva, 2015) . Obstruction of pathways that control cholesterol metabolism can cause retinal cholesterol accumulation which can have detrimental effects on normal retinal function.
One of the mechanisms the retina employs to eliminate cholesterol involves the activation of the reverse cholesterol transport pathway (RCT) (Zheng et al., 2015) . This pathway is actively used by the retina to transport cholesterol back to the liver in a multistep process (Mast et al., 2011) . RCT-dependent removal of cholesterol is first controlled by ATP-binding cassette transporters ABCA1 and ABCG1 (Pikuleva & Curcio, 2014; Ye et al., 2011) . These membrane-associated protein transporters are the major regulators of cellular cholesterol by acting as cholesterol efflux pumps that efflux cholesterol to lipid poor apolipoproteins (ApoA1 and ApoE) . Genetic manipulation studies have demonstrated that downregulation of ABCA1 leads to pathologic vessel thickening and hardening (Sene et al., 2013) . Additionally, patients with ABCA1 mutations are diagnosed with Tangier disease, a disease that is characterized by a severe reduction in HDL (Murano et al., 2016) . Secondly, the retina relies on enzymatic elimination of cholesterol by cytochrome P450 enzymes (CYPs) (Zheng et al., 2015) . CYPs metabolize cholesterol to more soluble oxysterols that rapidly diffuse to the systemic circulation. The three main CYPs involved in cholesterol metabolism are CYP46A1, CYP27A1 and CYP11A1. All three of these CYPs are present in retinal tissues (Pikuleva, 2008) .
Abnormal cholesterol elimination in diabetic retina can lead to an increase in non-enzymatic oxidation and glycation. Oxidized and glycated LDL identified in the retina during diabetes were shown to induce retinal pericyte loss and oxidized LDL immunocomplexes and were implicated to play a role in diabetic retinopathy . Oxidized cholesterol, particularly 7-ketocholesterol (7kCh), is elevated in diabetes. 7kCh is a potent pro-apoptotic agent shown to activate caspases (Moreira, Larrayoz, Lee, & Rodriguez, 2009) . Elevated levels of 7hCh were recently shown in photodamaged retina and are suggested to play a role in photoreceptor degeneration after exposure to constant light (Rodriguez & Fliesler, 2009 ).
Sphingolipids
Diabetes has been shown to alter sphingolipid metabolism (Fox et al., 2006; Maines, French, Wolpert, Antonetti, & Smith, 2006; Skoura et al., 2007) . Sphingolipids are an important class of biologically active lipids that have critical roles in regulating cell growth, death, inflammation, adhesion and migration (Hannun & Bell, 1989) . One of the main secondary messengers involved in sphingolipid metabolism is known as ceramide. This secondary messenger is a pro-apoptotic sphingolipid that accumulates in endothelial cells as well as immune cells (Obeid, Linardic, Karolak, & Hannun, 1993) . Ceramide holds a central position in sphingolipid metabolism and can be formed by de novo synthesis by the action of serine palmitoyl transferase followed by ceramide synthase and dihydroceramide desaturase, or through the breakdown of sphingomyelin by sphingomyelinases (Hannun & Obeid, 2008) . Ceramide is then either phosphorylated by ceramide kinase, glycosylated by glucosyl or galactosyl ceramide synthases, converted to sphingomyelin by addition of phosphocholine headgroup from phosphatidylcholine through the action of sphingomyelin synthase, or broken down by several ceramidases leading to the formation of sphingosine. Phosphorylation of sphingosine by one of two sphingosine kinases leads to generation of sphingosin-1-phosphate, which can be dephosphorylated by intracellular or extracellular phosphatases to regenerate sphingosine (Busik et al., 2012; Hannun & Obeid, 2008) . Alternatively, S1P ligase can irreversibly cleave S1P to generate ethanolamine phosphate and hexadecenal.
The complexity and interconnection of sphingolipid pathways explains diverse and sometimes opposing effects of sphingolipids in different cell types. In general, ceramides are known to have pro-inflammatory and pro-apoptotic effects, whereas S1P has pro-survival, proliferation and migration effects (Hla, 2004) . Thus, sphingolipid metabolism is often called sphingolipid rheostat where cross-conversion between sphingolipid species determines the final physiologic outcome.
Biologically active ceramide is mainly produced by the action of sphingomyelinases (Dumitru, Zhang, Li, & Gulbins, 2007) . Based on the pH optimum, sphingomyelinases are classified into three different types: acid, neutral and alkaline (Goni & Alonso, 2002) . Alkaline sphingomyelinase is only expressed in the gut (Nilsson & Duan, 1999) . Acid and neutral sphingomyelinases are ubiquitously expressed in most tissues (Busik et al., 2012) . Although both acid and neutral sphingomyelinases are expressed in the retina and BM cells, only acid sphingomyelinase (ASM) is activated by diabetes (Opreanu et al., 2011) . Activation of ASM leads to higher rates of sphingomyelin-ceramide conversion causing retinal endothelial damage in the diabetic retina, macrophage and microglia activation, and circulating angiogenic cells (CAC) dysfunction . Importantly, inhibition of ASM either in the retina, or in the bone marrow has been shown to prevent diabetes-induced vascular degeneration (Fig. 1) .
In the retina endothelial cells have the highest ASM expression and ASM level is upregulated by diabetes in retinal endothelium (Opreanu et al., 2011) . Dietary supplementation with fish oil prevented diabetes-induced ASM upregulation in retinal endothelium, as well as retinal vascular permeability and the development of acellular capillaries in diabetic rat model (Opreanu et al., 2011) . Whole body ASM-/-mice were protected from retinal ischemiareperfusion injury (Opreanu et al., 2011) , and inhibition of ASM in HREC protected from cytokine-induced proinflammatory changes . These data support the hypothesis that diabetes-induced activation of ASM in retinal endothelia cells contributes to DR pathogenesis.
Apart from the important role of lipids in cell signaling there is also a well-established literature indicating that presence of ceramide as well as cholesterol and oxysterols in a lipid bilayer causes a change in ''viscosity" of membranes (Goni & Alonso, 2006; Song & Waugh, 1993; Stancevic & Kolesnick, 2010) . In combination with Factin network, lipids determine such important biomechanical properties as plasma membrane fluidity and cell deformability. Membrane fluidity and deformability of endothelial cells are critically important for multiple endothelial cell functions including permeability, extravasation of immune cells, migration and angiogenesis. Moreover, decreased membrane fluidity and deformability of CACs leads to impaired release and migration, making them unavailable for vascular repair (Segal et al., 2006; .
As described above, diabetes is associated with increased levels of ceramide, as well as and cholesterol and 7kCh in the retina and CACs (Loomans et al., 2004) . These changes in membrane composition are associated with decreased membrane fluidity and deformability, impaired migration and extravasation capacity of CACs, which in turn prevents effective homing from BM to sites of vascular injury (Loomans et al., 2004; Segal et al., 2006) . Modifying membrane lipid composition of diabetic BM-derived cells, as well as endothelial cells may be beneficial for preventing retinal vascular degeneration . Measure of membrane fluidity could be used in the clinic as a mechanical biomarker to gain evidence of ongoing biomechanical stress and tissue damage due to diabetic dyslipidemia. Further, measures to correct membrane fluidity can be explored as a potential treatment strategy to improve endothelial cell as well as CACs function in diabetic patients.
Potential therapeutic targets
Due to the growing number of studies demonstrating the critical role dyslipidemia plays in progression of DR pathology, several potential therapeutic targets have been identified. Listed below are some of the therapeutic solutions that have been developed to target multiple lipid classes including fatty acids, triglycerides, cholesterol, and sphingolipids.
Resolvins and protectins
It is hypothesized that the shift from omega-3 fatty acids to omega-6 fatty acids seen in diabetic dyslipidemia causes increased levels of bioactive lipids, which contributes to the proinflammatory environment seen in early stages of DR. A recent clinical trial (PREDIMED) demonstrated that dietary intake of long chain omega 3 fatty acids deceased the risk of DR in type 2 diabetic patients (Sala-Vila et al., 2016) . One potential explanation for the beneficial effects of omega-3 fatty acids is the synthesis of resolvins. Resolvins are anti-inflammatory metabolites which are synthesized from eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) and are resolution-phase mediators of the acute inflammation response (Das, 2013) . Protectins are another type of ''resolution phase interaction products" that formed as a response to aspirin treatment. Although the formation of these new docosatriens (protectins) were first discussed in brain tissue it is now hypothesized that they are not limited to neural tissue and can be found in a wide range of cell types (Serhan & Petasis, 2011) . Commercially available resolvins and protectins have been shown to have beneficial functions in diseases such as Alzheimer's disease, obesity, diabetic wound healing, colitis, vascular inflammation, and dry eye disease (Claria, 2010; Hong & Lu, 2013; Li, He, Schwartz, Gjorstrup, & Bazan, 2010; Xu et al., 2010) . A complete list of disease models can be found in Serhan and Petasis (2011) .
Lipoxygenases (LOX)
Chronic low grade inflammation is widely considered a hallmark of DR (Schroder, Palinski, & Schmid-Schonbein, 1991; Vincent & Mohr, 2007) . Both systemic and retinal-specific factors contribute to inflammation in DR with retinal lipid dysregulation playing an important role in diabetes-induced pro-inflammatory changes (Goldberg, 1981 (Goldberg, , 2001 . Namely, there is a decrease in the ratio of anti-inflammatory omega3 vs. pro-inflammatory omega6 PUFA in the diabetic retina (Chen, Jump, Esselman, & Busik, 2007; Chen, Jump, Grant, Esselman, & Busik, 2003; Chen et al., 2005) . Combined with an increase in phospholipase A2 (PLA2) activity, this leads to an increase in free omega 6 PUFA, these omega-6 PUFA are then rapidly metabolized through different enzymatic pathways which include lipoxygenase (LOX), cytochrome P450 and cyclooxygenase and converted to proinflammatory bioactive lipid mediators including prostaglandins, HETEs and leukotrienes (Busik et al., 2012; Garg, Madhu, & Suneja, 2015) .
Specific oxygenases and their bioactive products in the retina depend on the age, stage of retinopathy and available substrates. Indeed, it was demonstrated that the initial inflammation and vasodegeneration in DR are mediated by 5-LOX, rather than 12/15-LOX enzyme products (Gubitosi-Klug, Talahalli, Du, Nadler, & Kern, 2008) . However, later neovascular stages are mediated by 12/15-LOX (Al-Shabrawey et al., 2008; Augustin, Grus, Koch, & Spitznas, 1997) . Specifically, studies have shown that in STZinduced diabetic model, which only progresses to vasodegenerative stage of DR, 5-LOX deficiency prevented retinal inflammation, leukostasis and the development of acellular capillaries, whereas 12/15-LOX deficiency did not have any effect on diabetesinduced retinal damage (Gubitosi-Klug et al., 2008) . However, in animal models of retinal neovascularization as well as in diabetic donor tissue with neovascularization expression of 12/15-LOX is significantly increased (Al-Shabrawey et al., 2011) . Inhibition of 12/15-LOX has also been shown to significantly decrease retinal neovascularization, and decrease levels of pro-inflammatory cytokines, and VEGF in diabetic rodents (Al-Shabrawey et al., 2011) . It was demonstrated that the effects of LOX are highly dependent on the available fatty acid substrate (Sapieha et al., 2011) . Thus, 5-LOX metabolite of omega 3 PUFA, 4-HDHA, has protective, anti-angiogenic effects, as opposed to damaging effects of omega 6-PUFA metabolites (Sapieha et al., 2011) .
Moreover, combined effects of 5-,12-and 15-LOX lead to synthesis of Lipoxin from AA. Lipoxins are secreted by immune cells and have been shown to play beneficial anti-inflammatory roles in a wide range of pathologies such as cancer, neurological disease, viral infections and diabetes (Chandrasekharan & Sharma-Walia, 2015; Fierro & Serhan, 2001 ). In the context of diabetes, lipoxins have been shown to not only be anti-inflammatory but also suppress induction of IL-6, TNF and VEGF (Das, 2013) . Since these cytokines are known to be elevated in patients with diabetic retinopathy, lipoxin based therapies could be beneficial in treating patients with DR.
Cytochrome P450 epoxygenase (CYP)
Similar to LOX, cytochrome P450 epoxygenase (CYP) pathway is active in the retina and the outcomes of this pathway activation depend on the stage of retinopathy and activity of downstream soluble Epoxide Hydrolase (sEH) enzymes (Capozzi, McCollum, & Penn, 2014; Imaoka, Hashizume, & Funae, 2005) . Indeed, CYP2C products of omega 6 and omega 3 PUFA oxidation, epoxyeicosatrienoic acid (11,12EET) and epoxydocosapentaenoic acid (19, when combined with an inhibitor of sEH, inhibited VCAM-1 and ICAM-1 expression and protein levels, as well as leukostasis in TNFa-induced HREC culture model, and an acute mouse model of retinal inflammation (Capozzi, Hammer, McCollum, & Penn, 2016) . Additionally, using a mouse model of laser-induced choroidal neovascularization (CNV), it has been shown that systemic administration of 17,18-epoxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid (17,18-EEQ), or 19,20-EDP reduced the size of CNV lesions and vascular leakage (Yanai et al., 2014) . The effects were attributed to inhibition of CD11b/ CD18 on the surface of leukocytes, an ICAM-1 on retinal vasculature to prevent leukocyte recruitment and leukocyte-mediated inflammation.
However, in oxygen-induced retinopathy (OIR) and CNV retinal neovascularization models, 19,20-EDP and activation of CYP2C increased OIR and CNV-induced lesions in a mouse model. sEH inhibition further worsened the pathology, supporting that CYP2C x3LCPUFA metabolites promote retinal pathological angiogenesis (Shao et al., 2014) . Although CYP2C products and inhibition of sEH could be beneficial at the early stages of DR, this strategy might promote neovascularization in the retina. Therefore, further studies are warranted to fully understand the role of CYP2C and sEH products in DR pathogenesis.
Liver X receptor (LXR)
Activation of mechanisms that promote retinal cholesterol elimination are highly warranted as potential therapeutic solutions for patients with DR due to the growing number of studies highlighting the important role cholesterol dysregulation plays in vascular pathologies like DR. Recent studies suggest that pharmacologic activation of Liver X receptor (LXRa/LXRb) signaling could offer such therapy since pharmacological activation of LXRs has been shown to prevent the formation of DR-like pathology in a diabetic mouse models (Hazra et al., 2012; Zelcer & Tontonoz, 2006) . Furthermore, complete loss of LXR signaling leads to the formation of acellular capillaries and accumulation of cholesterol in retinal and other tissues in the absence of hyperglycemia (Hazra et al., 2012) . This accumulation of cholesterol is suggested to be a result of a robust downregulation of cholesterol transporter proteins ABCA1 and ABCG1 in LXRa/b -/-animals when compared to wildtype (Calkin & Tontonoz, 2010; Hazra et al., 2012) . Not only does LXR signaling promote cholesterol metabolism by activating the RCT pathway but LXR activation has also been shown to prevent upregulation of NF-jB-dependent proinflammatory gene upregulation (Bensinger et al., 2008; Janowski et al., 1999; Joseph, Castrillo, Laffitte, Mangelsdorf, & Tontonoz, 2003) . Specifically, LXR has been shown to bind and subsequently stabilize the NCoR complex and thus inhibiting signaling through NF-jB response element on inflammatory gene promoters (Ogawa et al., 2004; Pascual et al., 2005) (Fig. 2) .
Thus, activation of LXR offers two beneficial consequences, promotion of cholesterol metabolism and repression of proinflammatory gene upregulation. Additionally, oxysterols, also known as cholesterol sensors, are endogenous ligands for LXRs (Janowski, Willy, Devi, Falck, & Mangelsdorf, 1996; Janowski et al., 1999) . Due to the beneficial actions of LXR signaling, several synthetic ligands have been formulated to activate LXR and serve as potential therapeutic targets to treat pathologies like DR (Beyea et al., 2007; Dong et al., 2015; Hazra et al., 2012; Quinet et al., 2004) .
Acid sphingomyelinase (ASM)
Furthermore, inhibition of ASM (ASM -/-animal model) prevents retinal inflammation and diabetes-induced microvascular degeneration (Fig. 1) . Interestingly, either inhibition of ASM in the retina and retinal cells, or in the bone marrow was effective Opreanu et al., 2010 Opreanu et al., , 2011 . When ASM is inhibited in the bone marrow, activation of BM-derived microglia-like cells in the retina, and thus inflammation can be prevented and CACs release and homing to retinal vasculature, and thus vascular repair is improved in a diabetic animal model Opreanu et al., 2010 Opreanu et al., , 2011 Tikhonenko et al., 2010) . ASM inhibition has also been shown to reduce ceramide levels in both CACs and BM cells . Since the pathogenesis of DR involves chronic lowgrade inflammation as well as dyslipidemia, therapies with antiinflammatory actions and the ability to prevent lipid dysregulation are highly desired (Goldberg, 2009; Semeraro et al., 2015) .
MicroRNAs (miR-15a)
Although diabetes-induced increase in ASM activity causes retinal vascular damage and diminishes vascular repair mechanisms, basal ASM expression is essential for normal retinal function and complete ASM deficiency leads to neurodegeneration, activation of microglia and loss of retinal function in ASM À/À mice (Dannhausen et al., 2015; Horinouchi et al., 1995) . miRNAs are known to function like dimmers, rather than an on/off switch as they inhibit, but do not lead to complete silencing of gene expression (He & Hannon, 2004) . Therefore, miRNAs could provide a feasible therapeutic approach for partial reduction rather than complete inhibition of ASM. In search of miRNAs that control ASM expression and are downregulated in diabetic retina, we found that miR-15a negatively regulates ASM expression through direct targeting of the 3 0 UTR of ASM mRNA . Moreover, miR-15a expression is reduced in diabetic retina and retinal cells. Importantly, in addition to ASM, miR-15a directly targets and inhibits VEGF-A, an important pro-angiogenic factor upregulated in diabetic retina (Fig. 3) . Therefore, targeting miR-15a offers a dual therapy that can address two detrimental hallmarks of DR, dysregulation of sphingolipid metabolism and ensuring inflammation, and angiogenesis. Fig. 2 . Diabetes leads to decreased levels of LXR. LXR downregulation leads to increased levels of inflammation and impaired cholesterol metabolism. Activation of LXR, via GW3965, prevents formation of diabetes-induced acellular capillary formation in an animal model of diabetes. 
Conclusions
Decades of research into understanding the disease cause and progression has led to the recent advances in available pharmacotherapy. However, due to the multifaceted nature of DR pathogenesis, a cure remains to be found. Further understanding of the complex molecular signaling events that occur during diabetic conditions has the potential to bring to light novel therapies for this detrimental disease. The diabetic milieu, in addition to being hyperglycemic, it is comprised of lipid dysregulation coupled with underlying chronic low-grade inflammation. Thus, to fully develop novel approaches to treat and cure DR, innovative therapies should address a combination of both hyperglycemia and dyslipidemia metabolic abnormalities.
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